The summary paper (part II) of the EAU PCa guidelines is now available online. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II—2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Philip Cornford European Urology European Association of Urology (EAU) authors.elsevier.com/c/1i-uV14kplyy…

More than 50% of high-profile scientific findings cannot be independently reproduced by other scientists. Lab research is the worst, with irreproducibility for top publications reaching nearly 90%. This is a waste of more than $28,000,000,000 from taxpayers in America alone.

SACKS: “The public schools in America are not run for the benefit of the kids. They're run for the benefit of the teachers unions. We saw this during COVID.”

Through our discussion about "innate templates of causal models" I came across an unpublished paper that, I believe, should be given renewed attention: "Contesting the Soul of Data Science": causality.cs.ucla.edu/blog/index.php… Gary Marcus David Deutsch Geoffrey Hinton Boris Sobolev

Judea Pearl Gary Marcus David Deutsch Geoffrey Hinton Boris Sobolev I agree with you that the “innate template of causal model” refers to the inborn frameworks in our brains that allow us to experience and understand the world. Therefore, biases can sometimes occur. You can call it whatever you want. Just like Newton, not an AI chatbot, are prone

Can I download “it” in Appstore?

Good read on an important topic. Nearly all geniuses were: - privately educated with elite tutors - introduced to complex topics young - around adults instead of peers when young Thoughts: -great contemporary thinkers should teach the youth -apprenticeships

Judea Pearl Boris Sobolev Gary Marcus David Deutsch Geoffrey Hinton If we interpret your neighbor’s thoughts based on your perspective about “innate template of causal model”. In the case of astrological predictions, what she said the so-called “evidence-based” approach here can be understood as a way of referring to the causal models already

PhilosopherMD M. Bolton Joshua D. Palmer, MD Tony Felefly Evan Thomas MD/PhD Shankar Siva Gerry Hanna Eric Hau Corinne Faivre-Finn Aisling Barry Jolyne O'Hare 💙 Jarushka Naidoo Patrick Forde Michael MacManus Gerard Walls RadOncResearch Raj Singh, MD Frank Harrell Let me try to answer your question in a more balanced way. The primary endpoint is the most important outcome, defined before the study begins. Statistical tests for the primary endpoint usually do not adjust for multiple testing, and the resulting p-value is considered the main

Too often, I see people talk about a replication as if the first study has established something, and the replication study is a double-check. What people often fail to understand is that we do not do replication studies to *check* a finding, but to *establish* a finding. 1/x

A bunch of Americans celebrating American values.

The guy is right -- this is not a conspiracy theory, this is what Billions of humanoids think in the 21st century, and what Mark Carney enables while trying to ignore.

Academic journals might be a lost cause but they'd probably be better if you had some non-academic practitioners serving as reviewers. Journalists have their problems too but they have much better bullshit detectors, for instance.

Ultrasound remains the most useful modality for diagnosis and monitoring of hydronephrosis, even able to identify prenatal cases. An example grading system is shown here. If intermediate or high risk on US, a voiding cystourethrogram (VCUG) can evaluate for vesicoureteral reflux

TRUE!!

M. Bolton PhilosopherMD Dong Nguyen Joshua D. Palmer, MD Tony Felefly Evan Thomas MD/PhD Shankar Siva Gerry Hanna Eric Hau Corinne Faivre-Finn Aisling Barry Jolyne O'Hare 💙 Jarushka Naidoo Patrick Forde Michael MacManus Gerard Walls RadOncResearch Raj Singh, MD Well put & for both frequentist & Bayesian paradigms it works so much better to have a pre-specified prioritization of assertions that also dictates the reporting order&context. Cook & Farewell argue correctly that multiplicity adjustments aren't needed. jstor.org/stable/2983471

Many of us know Dr Amol Akhade from his prolific conference posting & insightful trial analyses. Here we chat re: his clinical practice, healthcare systems in India, & more. W all the discussion on role SoMe in onc, I think we can all agree Dr. Akhade is such a force for good!

🚨 IMvigor011 Press Release High-risk MIBC, post-cystectomy 👉 ctDNA+ → Atezolizumab improved DFS & OS vs placebo ❌ IMvigor010 (Atezo, all-comers) = negative ✅ CheckMate-274 (Nivo, all-comers) = DFS benefit → SOC ✅ IMvigor011 (Atezo, ctDNA+) = precision win ➡️ From “treat